...
首页> 外文期刊>Journal of immunotherapy >A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors.
【24h】

A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors.

机译:用编码抗肿瘤抗原T细胞受体的慢病毒载体转导后,临床规模生成中央记忆样CD8 + T细胞的简化方法。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Adoptive transfer of antigen-specific CD8+ T cells can effectively treat patients with metastatic melanoma. Recent efforts have emphasized the in vitro generation of antitumor T cells by transduction of genes encoding antitumor T-cell receptors. At present, lentiviral vector-mediated transduction of CD8+ T cells relies on anti-CD3/CD28 bead stimulation; however, this method fails to efficiently expand CD8+ T cells. Herein we sought to establish a methodology for lentiviral vector transduction using optimal activating agents for efficient gene delivery and robust expansion of CD8+ T cells. To overcome the inability of anti-CD3/CD28 beads to efficiently expand CD8+ T cells, we evaluated alternative activating agents including feeder cells from allogeneic peripheral blood mononuclear cells and plate-bound anti-CD3 antibody. Analyses of gene transfer, cell phenotype, fold expansion, and biologic activities were used to determine the optimal methodology. Plate-bound anti-CD3 provided an ideal activation platform that afforded optimal lentiviral vector-mediated gene transfer efficiency (up to 90%), and coupled with peripheral blood mononuclear cells feeder cells yielded up to 600-fold expansion of CD8+ T cells within 12 days. The T-cell antigen receptor (TCR) engineered CD8+ T cells conferred specific antitumor activity and many displayed a central memory-like phenotype. The methodology described here could be readily applied for engineering CD8+ T cells with antitumor specificity for human adoptive immunotherapy.
机译:抗原特异性CD8 + T细胞的过继转移可以有效治疗转移性黑色素瘤患者。最近的努力强调了通过转导编码抗肿瘤T细胞受体的基因在体外产生抗肿瘤T细胞。目前,慢病毒载体介导的CD8 + T细胞转导依赖于抗CD3 / CD28珠刺激。但是,这种方法不能有效地扩增CD8 + T细胞。本文中,我们试图建立一种使用最佳活化剂进行慢病毒载体转导的方法,以实现有效的基因传递和CD8 + T细胞的稳健扩增。为了克服抗CD3 / CD28珠无法有效扩增CD8 + T细胞的能力,我们评估了替代激活剂,包括同种异体外周血单核细胞的饲养细胞和板结合的抗CD3抗体。基因转移,细胞表型,倍数扩展和生物活性的分析被用来确定最佳方法。板结合的抗CD3提供了理想的激活平台,该平台提供了最佳的慢病毒载体介导的基因转移效率(高达90%),并与外周血单核细胞饲养细胞相结合,可在12天内使CD8 + T细胞扩增多达600倍天。经T细胞抗原受体(TCR)工程改造的CD8 + T细胞具有特定的抗肿瘤活性,并且许多细胞都表现出中央记忆样表型。这里描述的方法可以很容易地应用于对人类过继免疫疗法具有抗肿瘤特异性的工程CD8 + T细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号